THE LELAND STANFORD JUNIOR UNIVERSITY

• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $2.1M

  Subcontractor to this prime · 3 sub-awards · latest Aug 3, 2026

  • Department of Energy
  • “STANFORD UNIVERSITY AI4NS RESEARCH AND DEVELOPMENT”
  • “STANFORD UNIVERSITY-STAND ALONE AGREEMENT-ITEM LEVEL-R AND D”
  • “STANFORD UNIVERSITY-STANDALONE-ITEM LEVEL-R AND D”
• NORTHROP GRUMMAN SYSTEMS CORPORATION

  UEI VSBAFMDKTWL4

  $1.1M

  Subcontractor to this prime · 2 sub-awards · latest Oct 31, 2025

  • Department of the Air Force
  • “COLLEGES, UNIVERSITIES AND PROFESSIONAL SCHOOLS”
  • “TECHNICAL SERVICES”
• VANDERBILT UNIVERSITY MEDICAL CENTER

  UEI GYLUH9UXHDX5

  $750.4K

  Subcontractor to this prime · 2 sub-awards · latest Oct 29, 2026

  • Centers for Disease Control and Prevention
  • National Institutes of Health
  • “GENETIC AND STRUCTURAL BASIS FOR VIRUS NEUTRALIZATION - LINE ITEM 1, BASE YEAR: ANTIBODY DISCOVERY PHASE 1”
  • “IVY 5 - SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2”
• TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE

  UEI GM1XX56LEP58

  $720.1K

  Subcontractor to this prime · 2 sub-awards · latest May 8, 2026

  • National Institutes of Health
  • “IN THIS CONTRACT, THE BOYD LAB WILL CARRY OUT THE FOLLOWING ACTIVITIES: PROJECT 1: CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM A MICHIGAN HUMAN COHORT AND, SUBJECT TO AVAILABILITY, A HONG KONG HUMAN SUBJECT COHORT, FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. PROJECT 2: FROM A HUMAN COHORT IN PENNSYLVANIA, CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. IN ADDITION, INFLUENZASPECIFIC B CELLS WILL BE ISOLATED BY FLOW CYTOMETRIC SORTING FOLLOWING INFLUENZA VACCINATION, AND SINGLE-CELL PCR WILL BE CARRIED OUT TO AMPLIFY ANTIBODY HEAVY AND LIGHT CHAINS. WE WILL THEN SEQUENCE THOSE PCR AMPLICONS AND CLONE THEM INTO EXPRESSION VECTORS FOR GENERATION OF MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES WILL BE SHARED WITH OTHER PROJECT INVESTIGATORS FOR CHARACTERIZATION FOR BINDING TO INFLUENZA VACCINE COMPONENTS IN ELISA ASSAYS AND WITH HEMAGGLUTININ INHIBITION ASSAYS. WE WILL ANALYZE THE ANTIBODY GENE SEQUENCE DATA AND CORRELATE IT WITH THE BINDING AND OTHER PROTEIN ASSAY DATA FROM THE MONOCLONAL ANTIBODIES GENERATED. IN ADDITION WE WILL SEQUENCE ANTIBODY GENE LIBRARIES GENERATED FROM FERRETS IN THIS PROJECT, AND ATTEMPT TO CLONE THE HEAVY AND LIGHT CHAIN GENE SEQUENCES FROM FERRET CELLS THAT BIND INFLUENZA ANTIGENS, TO EXPRESS THE ANTIBODIES AS PROTEIN FOR FURTHER CHARACTERIZATION BY OTHER PROJECT INVESTIGATORS. WE WILL ANALYZE THE FERRET ANTIBODY GENE SEQUENCE DATA BY COMPARING THEM TO THE”
  • “SCOPE OF WORK IN THIS CONTRACT, THE BOYD LAB WILL CARRY OUT THE FOLLOWING ACTIVITIES: PROJECT 1: CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM A MICHIGAN HUMAN COHORT AND, SUBJECT TO AVAILABILITY, A HONG KONG HUMAN SUBJECT COHORT, FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. PROJECT 2: FROM A HUMAN COHORT IN PENNSYLVANIA, CREATE ANTIBODY GENE SEQUENCE LIBRARIES FROM PERIPHERAL BLOOD MONONUCLEAR CELLS OF SAMPLES TAKEN DURING SURVEILLANCE FOR INFLUENZA INFECTION, OR PRIOR TO AND FOLLOWING INFLUENZA VACCINATION. THESE LIBRARIES WILL BE SEQUENCED USING THE ILLUMINA MISEQ INSTRUMENT. DATA WILL BE ANALYZED TO EVALUATE B CELL CLONAL POPULATIONS AND CANDIDATE VACCINE-RESPONSIVE B CELLS. IN ADDITION, INFLUENZASPECIFIC B CELLS WILL BE ISOLATED BY FLOW CYTOMETRIC SORTING FOLLOWING INFLUENZA VACCINATION, AND SINGLE-CELL PCR WILL BE CARRIED OUT TO AMPLIFY ANTIBODY HEAVY AND LIGHT CHAINS. WE WILL THEN SEQUENCE THOSE PCR AMPLICONS AND CLONE THEM INTO EXPRESSION VECTORS FOR GENERATION OF MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES WILL BE SHARED WITH OTHER PROJECT INVESTIGATORS FOR CHARACTERIZATION FOR BINDING TO INFLUENZA VACCINE COMPONENTS IN ELISA ASSAYS AND WITH HEMAGGLUTININ INHIBITION ASSAYS. WE WILL ANALYZE THE ANTIBODY GENE SEQUENCE DATA AND CORRELATE IT WITH THE BINDING AND OTHER PROTEIN ASSAY DATA FROM THE MONOCLONAL ANTIBODIES GENERATED. IN ADDITION WE WILL SEQUENCE ANTIBODY GENE LIBRARIES GENERATED FROM FERRETS IN THIS PROJECT, AND ATTEMPT TO CLONE THE HEAVY AND LIGHT CHAIN GENE SEQUENCES FROM FERRET CELLS THAT BIND INFLUENZA ANTIGENS, TO EXPRESS THE ANTIBODIES AS PROTEIN FOR FURTHER CHARACTERIZATION BY OTHER PROJECT INVESTIGATORS. WE WILL ANALYZE THE FERRET ANTIBODY GENE SEQUENCE DATA BY COMPARI”
• REGENTS OF THE UNIVERSITY OF MICHIGAN

  UEI GNJ7BBP73WE9 · not in the directory yet

  $488.8K

  Subcontractor to this prime · 2 sub-awards · latest Jun 18, 2025

  • National Institutes of Health
  • “DR. MONTGOMERY AND TEAM WILL FACILITATE TOPMED DRC TASKS AIMED AT FUNCTIONAL GENOMICS INCLUDING ACCOMPLISHING MULTI-OMICS TASKS RELATED TO QTL-MAPPING, MULTI-OMICS INTEGRATION, RARE VARIANT ANALYSES AND QUALITY CONTROL. DR. MONTGOMERY AND/OR TEAM MEMBERS WILL ATTEND RELEVANT MULTI-OMICS CALLS, WORK TO DEVELOP ANALYSIS PLANS, PRESENT AND PUBLISH RESEARCH RESULTS AND WILL BE RESPONSIVE TO THE TOPMED DRC TEAM.”
• MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  UEI E2NYLCDML6V1

  $452.5K

  Subcontractor to this prime · 1 sub-award · latest Aug 18, 2025

  • National Aeronautics and Space Administration
  • “DESIGN AND DEVELOP THE FRONT END ELECTRONICS (FEE_ FOR THE ADVANCED X-RAY IMAGING SATELLITE (AXIS)”
• MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  UEI SN5KKUDR9LY8

  $449.2K

  Subcontractor to this prime · 1 sub-award · latest Jun 14, 2024

  • Department of the Air Force
  • “R&D-SCHOOLS, NON-MIT”
• REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE

  UEI GS3YEVSS12N6

  $203.7K

  Subcontractor to this prime · 1 sub-award · latest Jun 17, 2025

  • Department of the Air Force
  • “TASK TA 1.2 NEURO-SYMBOLIC SAFE LEARNING PHASE 1: SYMBOLIC METHODS SUCH AS COMPUTATION OF HAMILTON JACOBI SAFE SETS WILL BE AUGMENTED WITH NEURAL NETWORK TECHNIQUES FOR SPEEDING UP COMPUTATION AND THE RESULTING NEURO-SYMBOLIC SAFE SET CALCULATIONS WILL BE USED FOR EXPLICABLE SAFE LEARNING DESIGN TOOLS AND ALGORITHMS {DES AND ALG}. PHASE 2: SAFE LEARNING ALGORITHMS WILL BE MADE ROBUST TO ADVERSARIAL ATTACK {WP, ALG}. CURRENT GAN ATTACK MODELS ARE NOT ADEQUATE FOR ADDRESSING DISTRIBUTIONAL SHIFTS {ADVERSARIES CHANGING BEHAVIOR}. TOOLS FOR MULTI-AGENT SYSTEMS WILL BE HIGHLIGHTED. PHASE 3: NEURO-SYMBOLIC SAFE LEARNING HAS TO BE KEPT FRESH, EVEN WHEN LEARNING HAS SLOWED DOWN. SAFE ALGORITHMS HAVE TO BE KEPT FROM GOING "STALE" AND NEED TO BE RESET IF NO NEW DATA IS AVAILABLE TASK TA 1.6 COMPOSITIONAL NEURO-SYMBOLIC CONTROL AND LEARNING PHASE 1: WE WILL DEVELOP TOOLS FOR ASSESSING THE CONFIDENCE IN THE AGGREGATE MODELS BASED ON THE RICHNESS OF THEIR TRAINING DATA. USE OF NN {DEEP LEARNING TOOLS} AS COMPUTATIONAL AIDS FOR HIGH DIMENSIONAL SYMBOLIC DESIGNS {SOFT}. PHASE 2: PROBABILISTIC HYBRID VERIFICATION TOOLS FOR ANSR SYSTEMS, WITH THE USE OF NN FOR SCALABILITY OF THE ASSURANCE ALGORITHMS. PHASE 3: SCALABLE ALGORITHMS FOR PROBABILISTIC MODEL CHECKING {SOFT} IN THE FACE OF UNCERTAINTIES, INCLUDING REAL-TIME ADAPTATION OF SAFETY ASSURANCES. TASK TA 2.2 VERIFICATION OF NEURO-SYMBOLIC SYSTEMS. PHASE 1: DEVELOPMENT OF SIMULATION-BASED VERIFICATION TOOLS {VERIFAI} AND THE LEVEL SET TOOLBOX WITH ADVANCES IN MULTI-OBJECTIVE FALSIFICATION AND SCALABILITY {SOFT}. PHASE 2: BASED ON FEEDBACK BY THE USERS OF THE TA 1 TOOLS AND THE TA 2 DESIGN FLOW WE WILL MODIFY THE ALGORITHMS AND TOOLS TO PROVIDE BETTER EXPERIMENTAL OUTCOMES. ESPECIALLY FEATURED IN PHASE II WILL BE THE USE OF THE TOOLS ON MULTI-AGENT SYSTEMS. INCORPORATION OF PRIOR KNOWLEDGE, TRANSFER LEARNING FROM ONE DOMAIN TO THE OTHER WILL BE HIGHLIGHTED. PHASE 3: ASSESSMENT OF THE VERIFICATION TOOLS WHEN APPLIED T”
• KAISER FOUNDATION HOSPITALS

  UEI P1RTMASB37B5

  $192.5K

  Subcontractor to this prime · 1 sub-award · latest Apr 23, 2026

  • Office of the Assistant Secretary for Financial Resources
  • “"STAFF AT STANFORD UNIVERSITY WILL COLLABORATE WITH MEMBERS OF THE EVIDENCE-BASED PRACTICE CENTER (EPC), THE US PREVENTIVE SERVICES TASK FORCE (USPSTF), AND THE CANCER INTERVENTION AND SURVEILLANCE MODELING NETWORK (CISNET) TO CARRY OUT A MODELING ANALYSIS TO EVALUATE THE EFFECTIVENESS OF AND COMPARATIVE EFFECTIVENESS OF DIFFERENT STRATEGIES FOR COLORECTAL CANCER (CRC) SCREENING."”
• BROOKHAVEN SCIENCE ASSOCIATES LLC

  UEI R85KZ9JP3NM3

  $142.4K

  Subcontractor to this prime · 1 sub-award · latest Sep 17, 2026

  • Department of Energy
  • “RESEARCH & DEVELOPMENT”

• UNIVERSITY OF LOUISIANA AT LAFAYETTE

  UEI C169K7T4QZ96 · not in the directory yet

  $230K

  Subcontracted by this company · 1 sub-award · latest Apr 3, 2026

  • National Institutes of Health
  • “A MOLECULAR ATLAS FOR BENCHMAKING ADJUVANTS (NIH CONTRACT TITLE: ADJUVANT COMPARISON AND CHARACTERIZATION)”
• EMORY UNIVERSITY

  UEI S352L5PJLMP8

  $227.5K

  Subcontracted by this company · 1 sub-award · latest Aug 15, 2025

  • National Institutes of Health
  • “THE SUTHAR LABORATORY WILL COMPLETE THE SARS-COV-2 MOUSE CHALLENGE AND LIVE VIRUS NEUTRALIZATION ASSAYS TO COMPARE RESPONSES ACROSS ADJUVANTED VACCINE DATASETS AS DESCRIBED IN THE CONTRACT PROPOSAL.”
• CURIA GLOBAL INC

  UEI ELCNZCS8GEA3

  $223.5K

  Subcontracted by this company · 3 sub-awards · latest Sep 23, 2026

  • National Institutes of Health
  • “(FORMAL CONTRACT TITLE: TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR T”
  • “"CURIA DESCRIPTION OF WORK NON-GMP MANUFACTURE OF APPROXIMATELY3 KILOGRAM OF STF-2586 AND REPROCESSING AND RETESTING OF STF- 2586 TASK 19: NON-GMP BATCH SUBTASK 19A: BATCH PROCEDURE/RECORD REVIEW AND APPROVAL SUBTASK 19B: MANUFACTURE, RELEASE, STABILITY "”
• SCRIPPS RESEARCH INSTITUTE

  UEI PHZJFZ32NKH4

  $201.3K

  Subcontracted by this company · 1 sub-award · latest Jan 16, 2026

  • National Institutes of Health
  • “INNOVATIONS IN FUNCTIONAL B-CELL EPITOPE DISCOVERY IN FOOD ALLERGENS”
• ACME BIOSCIENCE, INC.

  UEI JLADHHRK2K32 · not in the directory yet

  $186.4K

  Subcontracted by this company · 1 sub-award · latest Jul 1, 2025

  • National Institutes of Health
  • “THE MEDICINAL CHEMISTRY FOCUS ON PI4K IS TO IDENTIFY A NOVEL SERIES OF BACK-UP COMPOUNDS THAT ARE DIVERSE WITH OFF-TARGET TOXICITY AS WELL AS PHARMACOKINETIC PROPERTIES. ACME IS BEST SITED TO PERFORM THIS WORK GIVEN THEIR PREVIOUS EXPERIENCE IN SYNTHESIZING A LARGE A RANGE OF PI4K MOLECULES IN A TIMELY FASHION. THE COMPANY WILL SYNTHESIZE CHEMICALS THAT ARE DESIGNED BY THE STANFORD MEDICINAL CHEMISTS. THE SCOPE OF CHEMISTRY ACTIVITIES: TYPICAL ACTIVITIES INCLUDE SYNTHESIS OF FOCUSED COMPOUND LIBRARIES (TYPICALLY 20-200 COMPOUNDS PER LIBRARY) ON A SCALE OF 10-50 MG AND PURITY OF >95%. PROVIDE RELEVANT ANALYTICAL DATA INCLUDING 1H, 13C NMR AND LCMS. SYNTHESIS (TYPICALLY >50 MG) OF ANALOGS OF EACH STRUCTURE TO SUPPORT LEAD OPTIMIZATION AND LEAD SERIES IDENTIFICATION ACTIVITIES. SYNTHESIS OF KEY REFERENCE COMPOUNDS IN THE 0.5-5 G RANGE AND A PURITY OF ~95-98% (>98% WHEN RELEVANT). SYNTHESIS OF KEY INTERMEDIATES ON 5-50 G SCALE AND A PURITY OF ~95%. SCALE-UP OF SELECTED COMPOUNDS FOR ADVANCED IN-VIVO STUDIES ON A SCALE OF 5-50 G AND PURITY OF 95% (>98% WHEN RELEVANT). DEVISING CHEMICAL SYNTHETIC ROUTES WHEN NECESSARY. TECHNICAL JUSTIFICATION WHEN FACTORING IN THE ANTICIPATED EXTRA FEES AND LACK OF CLOSE PROXIMITY, COMBINED WITH A LONG- STANDING TRACK RECORD OF PRODUCTIVE AND COST-EFFECTIVE WORK DONE BY ACME ON OUR BEHALF, THEY WERE FELT TO BE THE OVERALL BEST VALUE.”
• ARAVASC, INC

  UEI C5QVPEJYM4K8

  $80.1K

  Subcontracted by this company · 1 sub-award · latest Jun 3, 2026

  • National Institutes of Health
  • “TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR T”
• INOTIV, INC

  UEI QYU7HDLDQK16

  $19.8K

  Subcontracted by this company · 1 sub-award · latest Jun 1, 2026

  • National Institutes of Health
  • “TO DEVELOP SMALL SYNTHETIC CHEMICAL MOLECULES AS BROADLY ACTIVE ANTIVIRAL FOR THE TREATMENT OF VIRAL INFECTIONS) ADVANCING A LEAD BROAD SPECTRUM ANTIVIRAL PI-KINASE INHIBITOR”

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.